A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies

Trial Profile

A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Ixazomib (Primary) ; Vorinostat
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 01 Jul 2014 Planned primary completion date changed from 1 May 2021 to 1 Jun 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top